Rvp-001

CNS Cancer

Reveal Pharmaceuticals Inc.Phase 2Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

7 Active assets in the CNS Cancer cohort.

Asset / Sponsor	Phase	Rating
CARMUSTINE SWOG Cancer Research Network	Phase 3	B
o6-benzylguanine SWOG Cancer Research Network	Phase 3	B
TZ-3321 Washington University School of Medicine	Phase 2	CCC
Bms-907351 National Cancer Institute (NCI)	Phase 2	CCC
Avapritinib M.D. Anderson Cancer Center	Phase 2	CCC

View all 13 →

Same molecule, other indications

Rvp-001 is also rated in:

benign neoplasm of brainDormant

B

Indicative ·

57 / 100

brain neoplasmDormant

B

Indicative ·

57 / 100

primary brain neoplasmDormant

B

Indicative ·

57 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.